Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUVOLA: Neoadjuvant Olaparib and Chemotherapy in BRCA-mutated Ovarian Cancer
NCT04261465Phase 2Unknown
- Sponsor
- Policlinico Gemelli
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib in High-Grade Serous Ovarian Carcinoma (HGSOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Policlinico Gemelli. Status: unknown.
02
Drugs
olaparib
03
Conditions
High-Grade Serous Ovarian Carcinoma (HGSOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04261465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04261465.